The plastic mesh devices are used to treat pelvic organ prolapse, a condition that causes the bladder, bowel or uterus to shift, often after a hysterectomy, childbirth or menopause. Health complications linked to the devices include urinary dysfunction, loss of sexual function, constipation, pelvic pain and infection.
In response to health concerns over the problem prone devices, the FDA elevated the product’s status from moderate to high risk and announced new federal scrutiny over them early this year.
California‘s lawsuit against the company cites false advertising and deceptive marketing, while Washington’s lawsuit alleges tens of thousands of violations of the state’s consumer protection law and seeks penalties that could reach millions of dollars.
Johnson & Johnson subsidiary Ethicon Inc., who marketed the mesh, calls the lawsuits unjustified and insists use of mesh implants are often the research-backed and preferred method of treating pelvic organ prolapse.
More articles on supply chain:
Electrode medical devices market to reach $1.45B by 2019
New gunshot wound device saves first life on battlefield
Scope-cleaning machine tied to super bugs still in use after FDA backs off recall
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
